JP2006521111A - 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 - Google Patents

血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 Download PDF

Info

Publication number
JP2006521111A
JP2006521111A JP2006507160A JP2006507160A JP2006521111A JP 2006521111 A JP2006521111 A JP 2006521111A JP 2006507160 A JP2006507160 A JP 2006507160A JP 2006507160 A JP2006507160 A JP 2006507160A JP 2006521111 A JP2006521111 A JP 2006521111A
Authority
JP
Japan
Prior art keywords
ephb4
polypeptide
ephrin
protein
soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006507160A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006521111A5 (enExample
Inventor
クラスノペロフ，バレリー
ゾズリア，セルゲイ
ケルテズ，ナタリー
レディ，ラマチャンドラ
ギル，パルカシュ
Original Assignee
バスジーン セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バスジーン セラピューティクス， インコーポレイテッド filed Critical バスジーン セラピューティクス， インコーポレイテッド
Publication of JP2006521111A publication Critical patent/JP2006521111A/ja
Publication of JP2006521111A5 publication Critical patent/JP2006521111A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
JP2006507160A 2003-03-12 2004-03-12 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用 Pending JP2006521111A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US45443203P 2003-03-12 2003-03-12
US45430003P 2003-03-12 2003-03-12
PCT/US2004/007755 WO2004080425A2 (en) 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011157200A Division JP2011256179A (ja) 2003-03-12 2011-07-15 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用

Publications (2)

Publication Number Publication Date
JP2006521111A true JP2006521111A (ja) 2006-09-21
JP2006521111A5 JP2006521111A5 (enExample) 2007-05-24

Family

ID=32994555

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006507160A Pending JP2006521111A (ja) 2003-03-12 2004-03-12 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
JP2006507095A Expired - Fee Related JP4762889B2 (ja) 2003-03-12 2004-03-12 血管形成及び腫瘍成長を阻止するための核酸化合物
JP2011157200A Pending JP2011256179A (ja) 2003-03-12 2011-07-15 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2006507095A Expired - Fee Related JP4762889B2 (ja) 2003-03-12 2004-03-12 血管形成及び腫瘍成長を阻止するための核酸化合物
JP2011157200A Pending JP2011256179A (ja) 2003-03-12 2011-07-15 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用

Country Status (6)

Country Link
US (5) US7585967B2 (enExample)
EP (2) EP1606305A4 (enExample)
JP (3) JP2006521111A (enExample)
AU (3) AU2004220459B2 (enExample)
CA (2) CA2518898A1 (enExample)
WO (2) WO2004080418A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011256179A (ja) * 2003-03-12 2011-12-22 Vasgene Therapeutics Inc 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
WO2004028551A1 (en) 2002-09-24 2004-04-08 The Burnham Institute Novel agents that modulate eph receptor activity
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
CA2559554A1 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
EP1799867A2 (en) * 2004-09-23 2007-06-27 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
DE102004054016A1 (de) * 2004-11-09 2006-05-11 Robert Bosch Gmbh Steuergerät zum Steuern und/oder regeln mindestens einer Fahrzeugfunktion
ES2556272T3 (es) * 2004-11-18 2016-01-14 The Board Of Trustees Of The University Of Illinois Constructos de ARNsi multicistrónico para inhibir tumores
WO2006074392A2 (en) * 2005-01-06 2006-07-13 Genentech, Inc. Cancer prognostic, diagnostic and treatment methods
US7582438B2 (en) 2005-01-27 2009-09-01 Burnham Institute For Medical Research EphB receptor-binding peptides
FR2889200B1 (fr) 2005-07-27 2008-01-04 Inst Vaisseaux Et Du Sang Ass Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
CA2623387A1 (en) * 2005-09-23 2007-04-05 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
KR101617108B1 (ko) 2006-01-20 2016-04-29 제넨테크, 인크. 항-ｅｐｈｒｉｎｂ２ 항체 및 그의 사용 방법
DK2056845T3 (da) 2006-08-08 2017-11-27 Rheinische Friedrich-Wilhelms-Universität Bonn Struktur og anvendelse af 5'-phosphat-oligonukleotider
WO2009006336A1 (en) * 2007-06-28 2009-01-08 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
EP2185594B1 (en) * 2007-08-13 2016-04-06 VasGene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
AU2008328754B2 (en) * 2007-11-29 2015-04-16 Molecular Health Gmbh Novel tissue protective erythropoietin receptor (NEPOR) and methods of use
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
WO2018110374A1 (ja) * 2016-12-14 2018-06-21 国立大学法人信州大学 殺細胞効果を有するキメラ抗原受容体遺伝子改変リンパ球
WO2020146723A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Functional analysis of cancer cells
JP7540010B2 (ja) * 2020-05-28 2024-08-26 サイトベイ インコーポレイテッド 細胞病理染色
EP4105328A1 (en) 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
US20250339504A1 (en) * 2022-05-18 2025-11-06 National Cancer Center Cancer vaccine with use of common cancer antigen cocktail, tcr/car-t cell therapeutic, companion diagnostic method, and method for diagnosing risk of cancer onset by detecting circulating tumor cells

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501701A (ja) * 1994-07-20 1998-02-17 ジェネンテック インコーポレイテッド Ｈｔｋリガンド
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
WO2002063037A2 (en) 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
WO2003000113A2 (en) * 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003004057A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
ES2230537T3 (es) 1991-06-21 2005-05-01 The Walter And Eliza Hall Institute Of Medical Research Una tirosina quinasa de tipo receptor (quinasa de tipo eph/elk hunaba-henki y uso de la misma.
AU3482493A (en) 1992-01-22 1993-09-01 New England Deaconess Hospital Novel protein tyrosine kinases
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
DK1167384T3 (da) 1992-10-28 2007-04-10 Genentech Inc Vaskular endotheliel cellevækstfaktor antagonister
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
JPH08505765A (ja) 1992-11-13 1996-06-25 アムジエン・インコーポレーテツド Ｅｃｋ受容体リガンド
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
ES2152753B1 (es) 1993-03-29 2001-09-01 Ct Investig Energeticas Ciemat Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
WO1996003043A1 (en) 1994-07-26 1996-02-08 Rutgers, The State University Of New Jersey Human brain specific kinase
US5795734A (en) * 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
EP0787148B1 (en) 1994-10-27 2004-04-07 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
AU710696C (en) 1995-09-08 2002-10-24 Genentech Inc. VEGF-related protein
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
AUPN727795A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel receptor-type tyrosine kinase and use thereof
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6413730B1 (en) * 1996-07-05 2002-07-02 Mount Sinai Hospital Corporation Method for identifying compounds that inhibit or enhance activation of a transmembrane ligand for a receptor tyrosine kinase
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
DK1325932T5 (da) 1997-04-07 2005-10-03 Genentech Inc Anti-VEGF antistoffer
WO1998045708A1 (en) 1997-04-08 1998-10-15 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6440954B1 (en) * 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
WO1999008696A1 (en) 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
JP2001518318A (ja) * 1997-10-02 2001-10-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド Ｌｅｒｋ−２媒介細胞接着の調節
US6423685B1 (en) * 1998-03-05 2002-07-23 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
EP0999278B1 (en) 1998-10-02 2004-03-31 Universite Paris Vii Vascular specific regulatory elements contained in the desmin 5' flanking region
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
DK1135153T3 (da) * 1998-11-20 2005-08-15 Genentech Inc Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
AU2658701A (en) * 2000-01-06 2001-07-16 Hospital For Sick Children, The Methods of modulation of the immune system
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
WO2001072765A1 (en) * 2000-03-28 2001-10-04 Isis Pharmaceuticals, Inc. ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
AU2001266557A1 (en) * 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001081377A2 (en) 2000-04-21 2001-11-01 Amgen, Inc. Integrin/adhesion antagonists
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
AU2001283108A1 (en) 2000-08-03 2002-02-18 The University Of Utah Research Foundation Manipulation of arterial-venous identity
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7136808B2 (en) * 2000-10-20 2006-11-14 Microsoft Corporation Detection and correction of errors in german grammatical case
US7163808B2 (en) * 2000-11-20 2007-01-16 California Institute Of Technology Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
WO2002058538A2 (en) 2001-01-26 2002-08-01 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
CA2437194A1 (en) 2001-01-31 2002-08-08 Mount Sinai Hospital Methods for regulating the kinase domain of ephb2
JP2004532022A (ja) * 2001-03-26 2004-10-21 サーナ・セラピューティクス・インコーポレイテッド Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
AU2002311792A1 (en) 2001-03-30 2002-10-15 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
CA2448320A1 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Ribozyme based treatment of female reproductive diseases
JP2005500034A (ja) 2001-06-20 2005-01-06 プロション バイオテク リミテッド 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用
JP3876656B2 (ja) * 2001-07-13 2007-02-07 住友金属工業株式会社 管用ねじ継手
WO2003040317A2 (en) * 2001-11-02 2003-05-15 Pfizer Products Inc. Lung cancer therapeutics and diagnostics
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
WO2003094859A2 (en) 2002-05-10 2003-11-20 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
US20040110150A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
WO2004020468A2 (en) 2002-08-28 2004-03-11 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2002951409A0 (en) 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
AU2003260169B9 (en) * 2002-09-16 2011-06-09 The Queen Elizabeth Hospital Research Foundation Inc. Methods for regulating cancer
EP1560931B1 (en) * 2002-11-14 2011-07-27 Dharmacon, Inc. Functional and hyperfunctional sirna
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
CA2518898A1 (en) * 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
US20070207952A1 (en) * 2003-03-24 2007-09-06 Sequoia Pharmaceuticals Long Acting Biologically Active Conjugates
JP2006524693A (ja) 2003-04-11 2006-11-02 メディミューン，インコーポレーテッド ＥｐｈＡ２および非腫瘍性過増殖性細胞障害
WO2004092343A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
WO2005048917A2 (en) 2003-06-06 2005-06-02 Medimmune, Inc. Use of epha4 and modulator or epha4 for diagnosis, treatment and prevention of cancer
WO2005037232A2 (en) * 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
CN1905899B (zh) 2003-11-20 2011-09-28 医学免疫公司 EphA2激动性单克隆抗体及其使用方法
CA2559554A1 (en) 2004-03-12 2005-09-29 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2006034455A2 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501701A (ja) * 1994-07-20 1998-02-17 ジェネンテック インコーポレイテッド Ｈｔｋリガンド
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
WO2002063037A2 (en) 2001-02-02 2002-08-15 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for identifying functional nucleic acids
WO2003000113A2 (en) * 2001-06-20 2003-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003004057A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6014010481; 医学のあゆみ，２０００，　Ｖｏｌ．１９４　Ｎｏ．１０，　ｐ．８２４-８２８ , 2000
JPN6014010482; Ｂｉｏｔｈｅｒａｐｙ，１９９９，　Ｖｏｌ．Ｎｏ．２，　ｐ．１４７-１５３ , 1999
JPN6014010483; Ｃａｒｄｉｏｖａｓｃｕｌａｒ　Ｍｅｄ-Ｓｕｒｇ，２０００，　Ｖｏｌ．２　Ｎｏ．４，ｐ．６０-６７ , 2000

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011256179A (ja) * 2003-03-12 2011-12-22 Vasgene Therapeutics Inc 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物

Also Published As

Publication number Publication date
AU2004220459A1 (en) 2004-09-23
JP2011256179A (ja) 2011-12-22
JP2006519610A (ja) 2006-08-31
CA2518912A1 (en) 2004-09-23
US7585967B2 (en) 2009-09-08
AU2010238577A1 (en) 2010-11-18
CA2518898A1 (en) 2004-09-23
EP1605961A4 (en) 2009-11-11
EP1605961A2 (en) 2005-12-21
AU2004220525B2 (en) 2011-03-31
WO2004080425A3 (en) 2005-07-07
US20050164965A1 (en) 2005-07-28
US20070031435A1 (en) 2007-02-08
WO2004080418A3 (en) 2005-05-06
US7862816B2 (en) 2011-01-04
AU2004220525A1 (en) 2004-09-23
WO2004080425A2 (en) 2004-09-23
US20100093831A1 (en) 2010-04-15
US8063183B2 (en) 2011-11-22
AU2004220459B2 (en) 2010-08-05
EP1606305A4 (en) 2009-06-24
US20050084873A1 (en) 2005-04-21
WO2004080418A2 (en) 2004-09-23
US20110129482A1 (en) 2011-06-02
AU2010238577B2 (en) 2012-05-24
JP4762889B2 (ja) 2011-08-31
EP1606305A2 (en) 2005-12-21

Similar Documents

Publication Publication Date Title
JP2011256179A (ja) 血管形成及び腫瘍増殖阻害用ポリペプチド化合物及びその応用
JP5219513B2 (ja) 血管形成及び腫瘍増殖阻害用ポリペプチド化合物
US8273858B2 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20110213127A1 (en) Methods for using and identifying modulators of delta-like 4
AU2007338734A1 (en) Methods for using and identifying modulators of delta-like 4
AU2006287228B2 (en) Methods for using and identifying modulators of Delta-like 4
KR101798664B1 (ko) 필라델피아 염색체 양성 백혈병의 치료를 위한 피엘지에프의 억제
KR20140103122A (ko) 신경교종을 치료하기 위한 조성물 및 방법
CN100541198C (zh) 诊断和治疗癌症的方法和用于其中的组合物
WO2012068477A1 (en) Methods and compositions for inhibiting angiogenesis and tumor growth
Ong Characterization of granulin gene expression in wounds and myelogenous leukemic cells
Furuta IL-25 Causes Apoptosis of IL-25R

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100420

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100720

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20100720

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100818

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110715

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110907

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20111111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140630

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150210